All News

Abstract 1718: Immune checkpoint inhibitors (ICI) in pre-existing #SLE Compared to non-SLE pts, those with SLE receiving ICIs had: 🔹 ↑ risk of thrombocytopenia & pancytopenia 🔹 No significant difference in all-cause mortality @RheumNow #ACR25 https://t.co/N1iOvxbsAZ

https://x.com/AkhilSoodMD/status/1982921999350718964/photo/1

IL-5 agents may in fact work for severe EGPA manifestations Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients @RheumNow #ACR25 https://t.co/slUpAT9mWo

https://x.com/Dr_Brian_MD/status/1982922182314561831/photo/1

The first father-daughter session at ACR? Brilliant session in diagnostic thinking and mimics in rheumatology from @LCalabreseDO and @CCalabreseDO, teasing apart heuristics, biases, and examples straddling the ID-Rheum divide. Well worth catching on the replay #ACR25 @RheumNow https://t.co/16FEqVyDGg

ANCA status does not inform IL-5 agent response in EGPA patients Terrier et al. analyzed the OLE of MANDARA and compared ANCA+ and ANCA- subgroups: - similar rates of remission - similar rates of GC withdrawal - comparable relapse rates @RheumNow #ACR25 Abst 1594

Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu

https://x.com/AkhilSoodMD/status/1982909416413507694/photo/1

When MAS is suspected. Soluble IL2 receptor alpha and CXCL9 may be useful (however t cell lymphomas and viral infections like hepatitis may also have them) #ACR25 @RheumNow Key takeaways below https://t.co/wJv1dvwU88

https://x.com/bella_mehta/status/1982907032161435673/photo/1

Functional MRI studies have been out there for a while, but mechanisms and significance underlying fMRI findings are unclear fMRI study in 38 active PsA pts w/ significant fatigue Altered functional connectivity between posterior insula to cerebellum & superior frontal gyrus https://t.co/3s9CJUg2uN

https://x.com/AurelieRheumo/status/1982908088039682293/photo/1

Soluble IL2 receptors help assess macrophages behavior. Ferritin also asses the same in Macrophage activation syndrome. ADA2 is the newer biomarker for hemophagocytic syndromes. #ACR25 @RheumNow Interferon gamma also a newer important target in MAS https://t.co/7sWwninBTM

https://x.com/bella_mehta/status/1982903391761441134/photo/1

Simultaneous measurements if S100, Ferritin and IL-18 increase diagnostic utility of these biomarkers in Stills disease. @RheumNow #Acr25 https://t.co/3wmijNcpVY

https://x.com/bella_mehta/status/1982902634936967446/photo/1

Low percentage of glycosylated Ferritin was more specific for Stills disease but not used frequently in clinical practice. @RheumNow #ACR25 https://t.co/wTK1eIcSKX

https://x.com/bella_mehta/status/1982901974468345967/photo/1

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

https://x.com/Yuz6Yusof/status/1982900831436615909/photo/1

Biomarkers in Stills disease and MAS. #ACR25 @RheumNow IL 6 may not be helpful compared to CRP, and IL 1 beta is difficult to measure IL-18 seems to be the best one. https://t.co/u3oBTd4eaP

https://x.com/bella_mehta/status/1982899918483374500/photo/1

#ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airway features of #EGPA improved with Benralizumab/Mepolizumab. Provides assurance to use more in real-world @RheumNow https://t.co/i78xXojGja

https://x.com/Yuz6Yusof/status/1982897181272289562/photo/1

IL- 18 go together sometimes with glycolytic enzymes such as aldolase Also MAS may not be a switch on and off mechanism. Lastly MAS with Stills may have increased IL18 levels but not in other disease like SLE #ACR25 @RheumNow https://t.co/BW1fD7usBT

https://x.com/bella_mehta/status/1982896532279177424/photo/1

What do we know about IL-18 Normal levels less than 500 Non specific 500 to 15000 Stills (quiet) 2000 to 10000 Mas/glares 20000 and more @RheumNow #ACR25 https://t.co/ZAltAD5Q8V

#ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

https://x.com/Yuz6Yusof/status/1982894724118917460/photo/1

AOSD And sJIA aren't the same disease!!!. Another take on this by Scott Canna..because the clinical syndrome might have somethings distinct!! #acr25 @RheumNow

Dr. Gensler gave a fantastic talk on SpA mimics ☝️Not all IBP is axSpA - interpret in the appropriate context + imaging WOF other mimics 🔸 Sacral insufficiency fractures 🔸 Infections 🔸DISH #ACR25 @RheumNow https://t.co/7TIqyp5rYe

In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa

https://x.com/synovialjoints/status/1982892555382518024/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow & its faculty.

Topics

All News

Do you get our email newsletter?